Abby M Bailey1, Regan A Baum1, Karolyn Horn1, Tameka Lewis2, Kate Morizio1, Amy Schultz2, Kyle Weant3, Stephanie N Justice4. 1. Department of Pharmacy, University of Kentucky HealthCare, Lexington, Kentucky. 2. Department of Pharmacy, Charleston Area Medical Center, Charleston, West Virginia. 3. Department of Pharmacy, Medical University of South Carolina, Charleston, South Carolina. 4. Department of Pharmacy, St. Claire Regional Medical Center, Morehead, Kentucky.
Abstract
BACKGROUND: Intranasal (IN) medication delivery is a viable alternative to other routes of administration, including intravenous (IV) and intramuscular (IM) administration. The IN route bypasses the risk of needle-stick injuries and alleviates the emotional trauma that may arise from the insertion of an IV catheter. OBJECTIVE: This review aims to evaluate published literature on medications administered via the IN route that are applicable to practice in emergency medicine. DISCUSSION: The nasal mucosa is highly vascularized, and the olfactory tissues provide a direct conduit to the central nervous system, bypass first-pass metabolism, and lead to an onset of action similar to IV drug administration. This route of administration has also been shown to decrease delays in drug administration, which can have a profound impact in a variety of emergent scenarios, such as seizures, acutely agitated or combative patients, and trauma management. IN administration of midazolam, lorazepam, flumazenil, dexmedetomidine, ketamine, fentanyl, hydromorphone, butorphanol, naloxone, insulin, and haloperidol has been shown to be a safe, effective alternative to IM or IV administration. As the use of IN medications becomes a more common route of administration in the emergency department setting, and in prehospital and outpatient settings, it is increasingly important for providers to become more familiar with the nuances of this novel route of medication delivery. CONCLUSIONS: IN administration of the reviewed medications has been shown to be a safe and effective alternative to IM or IV administration. Use of IN is becoming more commonplace in the emergency department setting and in prehospital settings.
BACKGROUND: Intranasal (IN) medication delivery is a viable alternative to other routes of administration, including intravenous (IV) and intramuscular (IM) administration. The IN route bypasses the risk of needle-stick injuries and alleviates the emotional trauma that may arise from the insertion of an IV catheter. OBJECTIVE: This review aims to evaluate published literature on medications administered via the IN route that are applicable to practice in emergency medicine. DISCUSSION: The nasal mucosa is highly vascularized, and the olfactory tissues provide a direct conduit to the central nervous system, bypass first-pass metabolism, and lead to an onset of action similar to IV drug administration. This route of administration has also been shown to decrease delays in drug administration, which can have a profound impact in a variety of emergent scenarios, such as seizures, acutely agitated or combative patients, and trauma management. IN administration of midazolam, lorazepam, flumazenil, dexmedetomidine, ketamine, fentanyl, hydromorphone, butorphanol, naloxone, insulin, and haloperidol has been shown to be a safe, effective alternative to IM or IV administration. As the use of IN medications becomes a more common route of administration in the emergency department setting, and in prehospital and outpatient settings, it is increasingly important for providers to become more familiar with the nuances of this novel route of medication delivery. CONCLUSIONS: IN administration of the reviewed medications has been shown to be a safe and effective alternative to IM or IV administration. Use of IN is becoming more commonplace in the emergency department setting and in prehospital settings.
Authors: Francisco Javier Gómez-Manzano; José Alberto Laredo-Aguilera; Ana Isabel Cobo-Cuenca; Joseba Rabanales-Sotos; Sergio Rodríguez-Cañamero; Noelia Martín-Espinosa; Juan Manuel Carmona-Torres Journal: Children (Basel) Date: 2022-04-29
Authors: Kenneth L Dretchen; Zack Mesa; Matthew Robben; Desmond Slade; Scott Hill; Claire Croutch; Kyle Kappeler; Michael Mesa Journal: Pharmacol Res Perspect Date: 2020-04
Authors: Jenny K W Lam; Chucky C K Cheung; Michael Y T Chow; Emily Harrop; Susie Lapwood; Stephen I G Barclay; Ian C K Wong Journal: Adv Drug Deliv Rev Date: 2020-11-01 Impact factor: 15.470
Authors: Anemone von Blomberg; Lara Kay; Susanne Knake; Sven Fuest; Johann Philipp Zöllner; Philipp S Reif; Eva Herrmann; Ümniye Balaban; Susanne Schubert-Bast; Felix Rosenow; Adam Strzelczyk Journal: CNS Drugs Date: 2020-05 Impact factor: 5.749